AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number
AP2369A
AP2369A AP2008004506A AP2008004506A AP2369A AP 2369 A AP2369 A AP 2369A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2369 A AP2369 A AP 2369A
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
AP2008004506A
Other languages
English (en)
Other versions
AP2008004506A0 (en
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx
Application granted granted Critical
Publication of AP2369A publication Critical patent/AP2369A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004506A0 AP2008004506A0 (en) 2008-06-30
AP2369A true AP2369A (en) 2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004506A AP2369A (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country Link
US (1) US7884117B2 (es)
EP (1) EP1979356B1 (es)
JP (1) JP4635089B2 (es)
KR (1) KR101029167B1 (es)
AP (1) AP2369A (es)
AU (1) AU2006327866B2 (es)
BR (1) BRPI0620354A2 (es)
CA (1) CA2634381C (es)
CR (1) CR10094A (es)
CU (1) CU23751B7 (es)
DK (1) DK1979356T3 (es)
EA (1) EA015513B1 (es)
EC (1) ECSP088558A (es)
ES (1) ES2435405T3 (es)
GE (1) GEP20104974B (es)
HR (1) HRP20130976T1 (es)
IL (1) IL191776A (es)
MA (1) MA30076B1 (es)
ME (1) ME00006B (es)
MY (1) MY151455A (es)
NO (1) NO20082482L (es)
NZ (1) NZ568692A (es)
PL (1) PL1979356T3 (es)
PT (1) PT1979356E (es)
RS (2) RS53029B (es)
WO (1) WO2007072153A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US10428019B2 (en) * 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
MX2013005507A (es) 2010-11-17 2013-07-17 Hoffmann La Roche Metodos para tratamiento de tumores.
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
RU2693381C2 (ru) 2012-07-13 2019-07-02 Уэйв Лайф Сайенсес Лтд. Асимметричная вспомогательная группа
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
KR102575327B1 (ko) 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7530297B2 (ja) 2018-11-14 2024-08-07 Ｕｂｅ株式会社 ジヒドロピロロピラゾール誘導体
AU2019413694B2 (en) * 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC Compositions and methods for the prevention and treatment of hearing loss
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
PT1838718E (pt) * 2005-01-10 2011-08-17 Pfizer Pirrolopirazoles, inibidores potentes da quinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
PL1979356T3 (pl) 2014-01-31
WO2007072153A8 (en) 2008-08-14
JP2009520805A (ja) 2009-05-28
IL191776A (en) 2013-03-24
NZ568692A (en) 2011-07-29
CR10094A (es) 2008-08-01
HK1128290A1 (en) 2009-10-23
CU20080115A7 (es) 2010-08-30
MEP0808A (xx) 2010-02-10
NO20082482L (no) 2008-07-02
ME00006B (me) 2010-02-10
RS53029B (sr) 2014-04-30
AU2006327866A1 (en) 2007-06-28
ECSP088558A (es) 2008-07-30
KR101029167B1 (ko) 2011-04-12
US7884117B2 (en) 2011-02-08
BRPI0620354A2 (pt) 2011-11-08
MY151455A (en) 2014-05-30
AU2006327866B2 (en) 2012-06-14
HRP20130976T1 (hr) 2013-11-22
CA2634381A1 (en) 2007-06-28
PT1979356E (pt) 2013-11-21
CA2634381C (en) 2011-03-08
CU23751B7 (es) 2012-01-31
AP2008004506A0 (en) 2008-06-30
WO2007072153A3 (en) 2007-10-25
IL191776A0 (en) 2008-12-29
MA30076B1 (fr) 2008-12-01
WO2007072153A2 (en) 2007-06-28
EA200801291A1 (ru) 2008-12-30
GEP20104974B (en) 2010-04-26
EA015513B1 (ru) 2011-08-30
RS20080281A (sr) 2009-09-08
US20090318440A1 (en) 2009-12-24
KR20080080567A (ko) 2008-09-04
DK1979356T3 (da) 2013-11-18
EP1979356B1 (en) 2013-09-18
JP4635089B2 (ja) 2011-02-16
EP1979356A2 (en) 2008-10-15
ES2435405T3 (es) 2013-12-19

Similar Documents

Publication Publication Date Title
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
IL184275A0 (en) Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en) Amine derivatives.
IL190078A0 (en) Kinase inhibitors
EG25271A (en) Fungicidal combinations.
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
AP2281A (en) Novel compounds.
SI1943243T1 (sl) Inhibotorji kinaz
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it) Semicabina per fumatori.
ITTO20050072U1 (it) Armadio-espositore, particolarmente per tabaccherie
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors
CY2449B1 (en) Multiple srengthened carton.
PL378279A1 (pl) Układ do osuszania gazów zwłaszcza dla komór klimatycznych